In Vitro and In Vivo Synergistic Activities of Linezolid Combined with Subinhibitory Concentrations of Imipenem against Methicillin-Resistant Staphylococcus aureus
Open Access
- 1 January 2005
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (1) , 45-51
- https://doi.org/10.1128/aac.49.1.45-51.2005
Abstract
Indifference or moderate antagonism of linezolid combined with other antibiotics in vitro and in vivo have mainly been reported in the literature. We have assessed the in vitro activities of linezolid, alone or in combination with imipenem, against methicillin-resistant Staphylococcus aureus (MRSA) strains using the dynamic checkerboard and time-kill curve methods. Linezolid and low concentrations of imipenem had a synergistic effect, leading us to evaluate the in vivo antibacterial activity of the combination using the rabbit endocarditis experimental model. Two MRSA strains were used for in vivo experiments: one was a heterogeneous glycopeptide-intermediate clinical S. aureus strain isolated from blood cultures, and the other was the S. aureus COL reference strain. Animals infected with one of two MRSA strains were randomly assigned to one of the following treatments: no treatment (controls), linezolid (simulating a dose in humans of 10 mg/kg of body weight every 12 h), a constant intravenous infusion of imipenem (which allowed the steady-state concentration of about 1/32 the MIC of imipenem for each strain to be reached in serum), or the combination of both treatments. Linezolid and imipenem as monotherapies exhibited no bactericidal activity against either strain. The combination of linezolid plus imipenem showed in vivo bactericidal activity that corresponded to a decrease of at least 4.5 log CFU/g of vegetation compared to the counts for the controls. In conclusion, the combination exhibited synergistic and bactericidal activities against two MRSA strains after 5 days of treatment. The combination of linezolid plus imipenem appears to be promising for the treatment of severe MRSA infections and merits further investigations to explore the mechanism underlying the synergy between the two drugs.Keywords
This publication has 44 references indexed in Scilit:
- In vivo efficacy of linezolid in combination with gentamicin for the treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureusInternational Journal of Antimicrobial Agents, 2004
- Efficacy of Linezolid plus Rifampin in an Experimental Model of Methicillin-Susceptible Staphylococcus aureus EndocarditisAntimicrobial Agents and Chemotherapy, 2003
- Linezolid-Resistant, Vancomycin-Resistant Enterococcus faecium Infection in Patients without Prior Exposure to LinezolidClinical Infectious Diseases, 2003
- In Vitro Activities of Linezolid Combined with Other Antimicrobial Agents against Staphylococci, Enterococci, Pneumococci, and Selected Gram-Negative OrganismsAntimicrobial Agents and Chemotherapy, 2003
- Combination Antibiotic Therapy for Infective EndocarditisClinical Infectious Diseases, 2003
- Emerging Linezolid-Resistant Enterococcus faecalis and Enterococcus faecium Isolated from Two Austrian Patients in the Same Intensive Care UnitEuropean Journal of Clinical Microbiology & Infectious Diseases, 2002
- Staphylococcus Heterogeneously Resistant to Vancomycin in China and Antimicrobial Activities of Imipenem and Vancomycin in Combination against ItJournal of Clinical Microbiology, 2002
- Comparative in vitro pharmacodynamics of BO-2727, meropenem and imipenem against Gram-positive and Gram-negative bacteriaClinical Microbiology & Infection, 1997
- Effect of sub‐inhibitory concentrations of antibiotics on the virulence of Staphylococcus aureusJournal of Applied Bacteriology, 1993
- Methods of testing combined antibiotic bactericidal action and the significance of the resultsJournal of Clinical Pathology, 1962